Wanbury Limited (WANBURY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wanbury Limited (WANBURY) has a cash flow conversion efficiency ratio of -0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-56.53 Million ≈ $-611.33K USD) by net assets (Rs1.07 Billion ≈ $11.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Wanbury Limited fund operations to measure how many days the company can operate on defensive assets alone.
Wanbury Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Wanbury Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Wanbury Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wanbury Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seoul Electronics & Telecom Co. Ltd
KQ:027040
|
-0.173x |
|
Eastland Equity Bhd
KLSE:2097
|
0.051x |
|
Bulten AB
ST:BULTEN
|
0.027x |
|
CO2 Energy Transition Corp. Common Stock
NASDAQ:NOEM
|
-0.002x |
|
Patriot One Technologies Inc
F:0PL
|
-0.493x |
|
Zevia Pbc
NYSE:ZVIA
|
0.003x |
|
Galleon Gold Corp
V:GGO
|
-0.008x |
|
Amogreentech Co.Ltd
KQ:125210
|
0.069x |
Annual Cash Flow Conversion Efficiency for Wanbury Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Wanbury Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see WANBURY market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs592.72 Million ≈ $6.41 Million |
Rs261.02 Million ≈ $2.82 Million |
0.440x | +209.30% |
| 2024-03-31 | Rs279.41 Million ≈ $3.02 Million |
Rs39.78 Million ≈ $430.23K |
0.142x | +123.60% |
| 2023-03-31 | Rs-328.16 Million ≈ $-3.55 Million |
Rs197.97 Million ≈ $2.14 Million |
-0.603x | +65.13% |
| 2022-03-31 | Rs-234.20 Million ≈ $-2.53 Million |
Rs405.23 Million ≈ $4.38 Million |
-1.730x | -1520.63% |
| 2021-03-31 | Rs-1.56 Billion ≈ $-16.90 Million |
Rs166.81 Million ≈ $1.80 Million |
-0.107x | +65.30% |
| 2020-03-31 | Rs-1.43 Billion ≈ $-15.51 Million |
Rs441.33 Million ≈ $4.77 Million |
-0.308x | -116.56% |
| 2019-03-31 | Rs-2.09 Billion ≈ $-22.63 Million |
Rs297.31 Million ≈ $3.22 Million |
-0.142x | +18.93% |
| 2018-03-31 | Rs-1.85 Billion ≈ $-19.97 Million |
Rs323.65 Million ≈ $3.50 Million |
-0.175x | +38.09% |
| 2017-03-31 | Rs-1.53 Billion ≈ $-16.58 Million |
Rs433.86 Million ≈ $4.69 Million |
-0.283x | -7.32% |
| 2016-03-31 | Rs-1.63 Billion ≈ $-17.65 Million |
Rs430.53 Million ≈ $4.66 Million |
-0.264x | -16.35% |
| 2015-03-31 | Rs-1.77 Billion ≈ $-19.16 Million |
Rs401.67 Million ≈ $4.34 Million |
-0.227x | +17.67% |
| 2014-03-31 | Rs-1.65 Billion ≈ $-17.85 Million |
Rs454.48 Million ≈ $4.92 Million |
-0.275x | +92.09% |
| 2013-03-31 | Rs-212.95 Million ≈ $-2.30 Million |
Rs741.21 Million ≈ $8.02 Million |
-3.481x | -980.07% |
| 2012-03-31 | Rs711.13 Million ≈ $7.69 Million |
Rs281.25 Million ≈ $3.04 Million |
0.395x | +747.00% |
| 2011-03-31 | Rs1.05 Billion ≈ $11.35 Million |
Rs49.02 Million ≈ $530.13K |
0.047x | -78.40% |
| 2010-03-31 | Rs1.92 Billion ≈ $20.81 Million |
Rs416.05 Million ≈ $4.50 Million |
0.216x | -52.49% |
| 2009-03-31 | Rs1.58 Billion ≈ $17.13 Million |
Rs720.95 Million ≈ $7.80 Million |
0.455x | +318.55% |
| 2007-03-31 | Rs1.29 Billion ≈ $13.96 Million |
Rs-268.83 Million ≈ $-2.91 Million |
-0.208x | -346.01% |
| 2006-03-31 | Rs1.01 Billion ≈ $10.94 Million |
Rs-47.21 Million ≈ $-510.60K |
-0.047x | -- |
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more